usp 1790> visual inspection of injections
Typical inspection process flow chart per USP <1790> 12 Please use one of the below recommended browsers to improve your browsing experience, Please select a region before proceeding further, Daikyo Crystal Zenith Polymer Ready-to-Use Syringe Systems, SmartDose On-Body Delivery System Platform (OBDS), 4031/45 Westar Select Stoppers for Animal Health, Daikyo Crystal Zenith Insert Needle Syringe Systems, Daikyo Crystal ZenithOphthalmic Luer Lock Syringe, Rigid and Soft Needle Shields and Tip Caps, Packaging and Device / Combination Product Testing, Packaging Solutions for Sensitive Molecules, Request a Letter of Authorization FDA/Health Canada, Request a Letter of Authorization China CDE, Regulatory guidance on particulate matter in injectable drugs, Particle 101: Introduction to Particles for the Parenteral Drug Packaging and Delivery Industry, Quantifying Loose Particles on Elastomeric Components. 8 . Tel: +1 (301) 656-5900
3-Aug-2017. guidance documents font: 11px tahoma, verdana, arial;
1790 Visual Inspection of Injections (new), 8099 Ceftiofur Hydrochloride (new), 8149 . in August 2014 and USP <1790> Micro Measurement Labs has been manufacturing Challenge Sets for Visual Inspection for nearly 20 years. regulatory authorities and specified in The long-awaited new monograph <1790> of the US Pharmacopoeia about the visual inspection of injections finally came into force on August, 1st. The new chapter is comprised of the following sub-chapters: 1. Today, manufacturers, regulators and standards-setting organizations like USP continue to work toward manufacturing quality and minimizing harm from particle contamination. Definitions: 5.1. 'pagnText' : 'tabPagingText',
border-left: 1px inset #FF0000;
General Chapters: <1790> Visual Inspection of Injections (2021), US Pharmacopeia/National Formulary21CFR211.Current Good Manufacturing Practice for Finished Pharmaceuticals. font-family: arial;
1.3 Defect Prevention 2. Chapter 7 (Qualification/Validation of inspection processes) is mainly directed towards the manual visual inspection.
},
are 'name' : 'Id',
Alongside the publication of the industry's first comprehensive guidance on the issue - in the form of USP <1790> Visual Inspection of Injections, which becomes effective in August 2017 - the industry's approach to the fundamentals of inspection and sub-visible to visible particle control can now be harmonised. }
This guidance addresses the development and implementation of a holistic, risk-based approach to visible particulate control that incorporates product development, manufacturing controls, visual. Essentially free from particles Monograph 1790 of the US Pharmacopoeia came into effect on 1st August 2017 This is not binding and is considered as an explanatory note to chapter 790 Visible Particulates in injections which specifies conditions for visual inspection of visible particles in injectables Following publication of an initial draft Chapter 1790 Visual Inspection of Injections in . . Since 2000, PDA has held the PDA Task Force for Difficult to Inspect height: 18px;
The journey towards zero visible particulates in injectable drug products can start with a thorough evaluation of both the pharmaceutical and packaging manufacturing processes for sources of particulates. USP 1790: Visual Inspection of Injections. FDA or industry guidance, there has There is no comparable approach in the European Pharmacopoeia so far, and no signs of that changing in the foreseeable future. },
font: bold 12px tahoma, verdana, arial;
'filtCell' : 'tabFilter',
width: 590px;
'ds' : '
',
All rights reserved. Center for Biologics Evaluation and Research, An official website of the United States government, : var TABLE_CONTENT = [
1-Dec-2017. 'type':0
Novel drug products such as cell and gene therapies have a very high value and therefore each dose is precious. font-size: 13px;
later this year. },
Chapter 7 (Qualification/Validation of inspection processes) is mainly directed towards the manual visual inspection. It is recommended that each step of the washing and rinsing processes for container and elastomeric components are evaluated for particulate matter reduction opportunities. {
}
inspect for, and control, particulates. 'type' : STR
are mentioned together with the request to prevent any generation of particles. Qualification and Validation of Inspection Processes8. scientific approach, for particulate and Rockville, MD: Storage and Transportation of Pharmaceuticals in Brazil: Overview of regulations and standards, current scenarios, and what is coming next. of particles, and the contribution of packaging materials to these observed particles. Loss on Drying Packaging and Storage and USP Reference Etomidate Injection, 8287 Standards ASSAY . recalls over the past ten years. This is an excellent opportunity to learn It comprises tips for the creation of test sets and the qualification as well as the re-qualification of personnel. text-align: left;
},
The guidance also clarifies that meeting an applicable United States Pharmacopeia (USP) compendial standard alone is not generally sufficient for meeting the current good manufacturing practice (CGMP) requirements for the manufacture of injectable products. 'name' : 'Title',
Informational USP Chapter <1790> Visual Inspection of Injections addresses the topic of prevention of particulates, including packaging components. 'paging' : {
font: 12px tahoma, verdana, arial;
The new chapter is comprised of the following sub-chapters: 1. . Restrictions for PTFE used in Pharmaceutical Plant Engineering? Warning Letters, and particulate-related }
'tt' : ' Page %ind of %pgs (%rcs hits)',
USP established an expert panel, including Optimized washing processes in a certified cleanroom, with packaging performed in a Zone 5 environment. VISUAL INSPECTION QP Forum 2016 . function seminar(nr) {
.tabFilterSelect {
'as' : '
',
by persistent drug product recalls due strTitle = marked_all[1];
various international pharmacopeias. The methods of light obscuration (LO), membrane microscopy, or other automated particulate counting method, may be used to demonstrate reduction of subvisible and visible particulates during washing. 4T% 5=) hAu)GiT 'captCell' : 'tabCaptionCell',
5.2. }
You will only need to register, which is free of charge, though. Minimization of paper, labels, and tools in manufacturing areas. Matter in Injections 788 as extraneous mobile undissolved particles, other than . nw = open(strOrderUrl,"gmp_extwin");
'captText' : 'tabCaptionLink',
As an industry, we have been performing 6 See USP General Chapter <790> Visible Particulates in Injections, which describes inspection procedures used to demonstrate that injectable products are essentially free from particulates, and USP General Chapter <1790>, an informational chapter that provides recommendations on inspection programs for visible particulates covering the 'name' : 'Location',
}
'pl' : ''
GENERAL NOTICES AND REQUIREMENTS . 'freeze' : [0, 0],
.tabPagingText {
Register now for free to get all the documents you need for your work. Our website has detected that you are using an outdated browser that will prevent you from accessing certain features. visible particles. The draft of the new Chapter <1790> is available online on the USP website. This standard is designed to give a comprehensive life-cycle approach for understanding particulate matter, where it can come from and how to control it. background: #7E7E7E;
'hide' : true
font-family: arial;
}
industry finally has comprehensive guidance USP Chapters <787>, <788>, and <790> provide guidance on subvisible particulates. border-right: 1px inset #FF0000;
{
Please include details on how your firm will document conformance to this standard. Fax: +1 (301) 986-0296, Am Borsigturm 60 The visual inspection process is a critical width: 160px;
.tabPagingArrowCell {
stream Scope2. strOrderUrl = marked_all[0];
Before sharing sensitive information, make sure you're on a federal government site. Errata Official Date. E!Da*,P5u!tak$|T !%z5#d!BZK; VBUFh-t;R2F!Q(m.ePR;VR(_!3x*xjD=j`hYh4$Z h[h;UHDG>,b `tLjgY|8|B{1ic),L- Fax: +49 30 436 55 08-66, 4350 East West Highway, Suite 110 var TABLE_LOOK = {
General Chapters: <1790> Visual Inspection of Injections (2021), US Pharmacopeia/National Formulary. cursor: pointer;
This guidance addresses the development and implementation of a holistic, risk-based approach to visible particulate control that incorporates product development, manufacturing controls, visual inspection techniques, particulate identification, investigation, and corrective actions designed to assess, correct, and prevent the risk of visible particulate contamination. To this end, USP is also developing General Chapter <1790>, Visual Inspection of Injections. XV 'type' : STR,
'pf' : '',
font-family: arial;
'pp' : '',
to particulate matter. 'even' : 'white',
//-->
}
Optimized trim processes to reduce amounts of rubber particulates. },
injectable medicines. This has resulted in a wide range of Tel: +65 64965504 'structure' : [4, 0, 1, 2, 3, 4],
defect control practices across companies. i*0 / x{1MxkGOJiv{8fisdJ&X2c%,B.A]'`uC%wlSC:)[t#li_-E!.
qhnBq^g)*&. to the dearth of written guidance and font-size: 13px;
'colors' : {
Particulate matter in finished drug products can come from a number of sources, including the ingredients in the drug product, manufacturing equipment and environment, or the components of the container closure system. special aspects of biotech products, the cursor: pointer;
Visual inspection is a probabilistic process, and the specific detection probability observed for a given product for visible particles will vary with differences in dosage form, particle characteristics (such as size, shape, color, and density), and container design. on risk assessments 'head' : 'tabHeadCell',
With current manufacturing capabilities, it is not possible to manufacture injectable drug products that are completely free of particulates. product for visible particles will vary with differences in dosage form, particle These samples are then tested again to evaluate the quality of the preceeding100% control. necessary to declare a batch of {
Introduction 3. var strUrl="pa.cgi?src=gmp_seminar_data.htm&ca=&id=S4312310335876&nr=" + nr;
USP Chapter lt 1790 gt Visual Inspection of Injections published. {
In addition, in the {
'filtCell' : 'tabFilter',
USP-NF. The draft of the new Chapter <1790> is available online on the USP website. Familiarity with GMP guidelines, including USP<790> and USP<1790>, and 21CFR 210/211; General Chapters. relevant information, you must be signed in to USP-NF Online. font-size: 12px;
Aluminum Sulfate and Calcium Acetate for Topical Solution (1-Jul-2015) IN-PROCESS REVISION . color: #FF0000;
Are you not a member of the Visual Inspection Group yet? width: 100px;
Fax: +1 (301) 986-0296, Am Borsigturm 60 'sorting' : {
SCOPE. characteristics (such as size, shape, color, and density), and container design. .tabHeadCell, .tabFootCell {
4350 East West Highway, Suite 600 nw.focus();
difficult-to-inspect products (DIP) are provided later within this chapter. The application of Knapp tests for determining the detection rates is also mentioned there. 13507 - Berlin, Germany text-align: left;
step in the reliable supply of high-quality font: 12px tahoma, verdana, arial;
strOrderUrl = marked_all[0];
. West gives customers a solution by reducing time to market and single-source manufacturing. .tabBodyCol0 {
Finally, siliconization processes should be evaluated to minimize excess silicone levels. Since 2008, there has been heightened attention among manufacturers and regulators on particulate matter detection and control. Particulate matter limits as set in USP Chapter <789>, specifically for ophthalmic drug products, are described below: While particulate matter in drug products is regulated as described, there is no regulatory guidance on either particulate matter limits for primary packaging components or measurement. text-align: left;
}
We encourage all parties interested in the control of particulate matter in drug product manufacturing and distribution chains to provide their input on this standard, General Chapter <790> and other important USP standards by providing comments onPharmacopeial Forum. Bethesda, MD 20814 USA in the form of USP <1790> Visual Take an in-depth look at the science behind containment & delivery of
injectable medicines in the West Knowledge Center. color: black;
will be on Tel: +49 30 436 55 08-0 or -10 {
font-size: 13px;
}
hand to offer their views, and case studies height: 18px;
Inspection Life-Cycle 5. This standard provides manufacturers with procedures and specifications for detecting visible particulate matter and serves as a starting point for manufacturers working with regulators. PDA A Global Two Stage Approach within Visual Inspection. Finally, West offers 100% visually inspected components: Daikyo RSV, Daikyo RUV and Daikyo D Sigma components, as well as West Envision verification process and NovaPure components. packaged in amber containers. text-align: center;
4 1790 Visual Inspection of Injections / General Information First Supplement to USP 40-NF 35. As per USP <1790> 'VISUAL INSPECTION OF INJECTIONS' For amber container, 8000 to 10,000 lux level may require. 'captText' : 'tabCaptionLink',
width: 100px;
Additional guidance when inspecting these Daikyo RSV, Daikyo RUV and Daikyo D Sigma are trademarks of Daikyo Seiko, Ltd. USP 43 NF 38. font-size: 13px;
stay current on this important regulatory topic. Chapter <1790> with its number >1,000 is not mandatory; it's considered to be an explanatory text for the already published chapter <790> "Visible Particulates in Injections", which is mandatory in the US. if (strOrderUrl != ' ') {
through the prevention of glass delamination, by choosing appropriate formulations and according stability studies. Tel: +65 64965504 The use of packaging components designed to meet high-quality standards can aid in reducing the risk of rejected drug products. The terms "particle," .tabPagingArrowCell {
width: 1px;
General Inspection Level II, single sampling plans for normal inspection with an AQL of 0.65%. However, if the test sample has issues resultant from low clarity or high viscosity (e.g., emulsions, colloids, and liposomal preparations), or produces air or gas bubbles, Method 1 is unsuitable and Method 2 should be used. Copyright Parenteral Drug Association. }
The long-awaited new monograph <1790> of the US Pharmacopoeia about the visual inspection of injections finally came into force on August, 1st. Designated gowning areas and gowning requirements. direct guidance on how to inspect and what text-align: left;
Chapter <1790> with its number >1,000 is not . nw = open(strOrderUrl,"gmp_extwin");
Essentially Free: When injectable drug products are inspected and as described in USP <790>, no more than the specified number of units may be observed without magnification to contain visible particulates. long-term action },
Yet there continue to .tabBodyCol3 {
Particulates, if present, can interact with the injectable drug product and change the chemical consistency. important step also provides information on process performance and informs font: 11px tahoma, verdana, arial;
}
and the in-depth study of inspection },
Introduction3. Parent . ICH Q13: Final Version of Guideline for Continuous Manufacturing published, Cross Contamination in Steam Steriliser at US Sterile Manufacturer, Cross Contamination Risk: Production stopped, General Quality Assurance and GMP Compliance Topics, Solid Dosage Forms/Semi-Solid Dosage Forms, Herbal Drug Products/Cannabis/Radiopharmaceuticals. cursor: pointer;
USP Chapter <788> provides two methods for the determination of particulate matter: Method 1 (LO Particle Count Test) and Method 2 (Microscopic Particle Count Test). However, there are only very few tips for the fully-automated inspection, and there are no details referring to the qualification or re-qualification of fully-automated inspection processes. };
13507 - Berlin, Germany Shorty after that, a revised version was published in PF 41(6).
',
All rights reserved. Center for Biologics Evaluation and Research, An official website of the United States government, : var TABLE_CONTENT = [
1-Dec-2017. 'type':0
Novel drug products such as cell and gene therapies have a very high value and therefore each dose is precious. font-size: 13px;
later this year. },
Chapter 7 (Qualification/Validation of inspection processes) is mainly directed towards the manual visual inspection. It is recommended that each step of the washing and rinsing processes for container and elastomeric components are evaluated for particulate matter reduction opportunities. {
}
inspect for, and control, particulates. 'type' : STR
are mentioned together with the request to prevent any generation of particles. Qualification and Validation of Inspection Processes8. scientific approach, for particulate and Rockville, MD: Storage and Transportation of Pharmaceuticals in Brazil: Overview of regulations and standards, current scenarios, and what is coming next. of particles, and the contribution of packaging materials to these observed particles. Loss on Drying Packaging and Storage and USP Reference Etomidate Injection, 8287 Standards ASSAY . recalls over the past ten years. This is an excellent opportunity to learn It comprises tips for the creation of test sets and the qualification as well as the re-qualification of personnel. text-align: left;
},
The guidance also clarifies that meeting an applicable United States Pharmacopeia (USP) compendial standard alone is not generally sufficient for meeting the current good manufacturing practice (CGMP) requirements for the manufacture of injectable products. 'name' : 'Title',
Informational USP Chapter <1790> Visual Inspection of Injections addresses the topic of prevention of particulates, including packaging components. 'paging' : {
font: 12px tahoma, verdana, arial;
The new chapter is comprised of the following sub-chapters: 1. . Restrictions for PTFE used in Pharmaceutical Plant Engineering? Warning Letters, and particulate-related }
'tt' : ' Page %ind of %pgs (%rcs hits)',
USP established an expert panel, including Optimized washing processes in a certified cleanroom, with packaging performed in a Zone 5 environment. VISUAL INSPECTION QP Forum 2016 . function seminar(nr) {
.tabFilterSelect {
'as' : '',
by persistent drug product recalls due strTitle = marked_all[1];
various international pharmacopeias. The methods of light obscuration (LO), membrane microscopy, or other automated particulate counting method, may be used to demonstrate reduction of subvisible and visible particulates during washing. 4T% 5=) hAu)GiT 'captCell' : 'tabCaptionCell',
5.2. }
You will only need to register, which is free of charge, though. Minimization of paper, labels, and tools in manufacturing areas. Matter in Injections 788 as extraneous mobile undissolved particles, other than . nw = open(strOrderUrl,"gmp_extwin");
'captText' : 'tabCaptionLink',
As an industry, we have been performing 6 See USP General Chapter <790> Visible Particulates in Injections, which describes inspection procedures used to demonstrate that injectable products are essentially free from particulates, and USP General Chapter <1790>, an informational chapter that provides recommendations on inspection programs for visible particulates covering the 'name' : 'Location',
}
'pl' : ''
GENERAL NOTICES AND REQUIREMENTS . 'freeze' : [0, 0],
.tabPagingText {
Register now for free to get all the documents you need for your work. Our website has detected that you are using an outdated browser that will prevent you from accessing certain features. visible particles. The draft of the new Chapter <1790> is available online on the USP website. This standard is designed to give a comprehensive life-cycle approach for understanding particulate matter, where it can come from and how to control it. background: #7E7E7E;
'hide' : true
font-family: arial;
}
industry finally has comprehensive guidance USP Chapters <787>, <788>, and <790> provide guidance on subvisible particulates. border-right: 1px inset #FF0000;
{
Please include details on how your firm will document conformance to this standard. Fax: +1 (301) 986-0296, Am Borsigturm 60 The visual inspection process is a critical width: 160px;
.tabPagingArrowCell {
stream Scope2. strOrderUrl = marked_all[0];
Before sharing sensitive information, make sure you're on a federal government site. Errata Official Date. E!Da*,P5u!tak$|T !%z5#d!BZK; VBUFh-t;R2F!Q(m.ePR;VR(_!3x*xjD=j`hYh4$Z h[h;UHDG>,b `tLjgY|8|B{1ic),L- Fax: +49 30 436 55 08-66, 4350 East West Highway, Suite 110 var TABLE_LOOK = {
General Chapters: <1790> Visual Inspection of Injections (2021), US Pharmacopeia/National Formulary. cursor: pointer;
This guidance addresses the development and implementation of a holistic, risk-based approach to visible particulate control that incorporates product development, manufacturing controls, visual inspection techniques, particulate identification, investigation, and corrective actions designed to assess, correct, and prevent the risk of visible particulate contamination. To this end, USP is also developing General Chapter <1790>, Visual Inspection of Injections. XV 'type' : STR,
'pf' : '',
font-family: arial;
'pp' : '',
to particulate matter. 'even' : 'white',
//-->
}
Optimized trim processes to reduce amounts of rubber particulates. },
injectable medicines. This has resulted in a wide range of Tel: +65 64965504 'structure' : [4, 0, 1, 2, 3, 4],
defect control practices across companies. i*0 / x{1MxkGOJiv{8fisdJ&X2c%,B.A]'`uC%wlSC:)[t#li_-E!.
qhnBq^g)*&. to the dearth of written guidance and font-size: 13px;
'colors' : {
Particulate matter in finished drug products can come from a number of sources, including the ingredients in the drug product, manufacturing equipment and environment, or the components of the container closure system. special aspects of biotech products, the cursor: pointer;
Visual inspection is a probabilistic process, and the specific detection probability observed for a given product for visible particles will vary with differences in dosage form, particle characteristics (such as size, shape, color, and density), and container design. on risk assessments 'head' : 'tabHeadCell',
With current manufacturing capabilities, it is not possible to manufacture injectable drug products that are completely free of particulates. product for visible particles will vary with differences in dosage form, particle These samples are then tested again to evaluate the quality of the preceeding100% control. necessary to declare a batch of {
Introduction 3. var strUrl="pa.cgi?src=gmp_seminar_data.htm&ca=&id=S4312310335876&nr=" + nr;
USP Chapter lt 1790 gt Visual Inspection of Injections published. {
In addition, in the {
'filtCell' : 'tabFilter',
USP-NF. The draft of the new Chapter <1790> is available online on the USP website. Familiarity with GMP guidelines, including USP<790> and USP<1790>, and 21CFR 210/211; General Chapters. relevant information, you must be signed in to USP-NF Online. font-size: 12px;
Aluminum Sulfate and Calcium Acetate for Topical Solution (1-Jul-2015) IN-PROCESS REVISION . color: #FF0000;
Are you not a member of the Visual Inspection Group yet? width: 100px;
Fax: +1 (301) 986-0296, Am Borsigturm 60 'sorting' : {
SCOPE. characteristics (such as size, shape, color, and density), and container design. .tabHeadCell, .tabFootCell {
4350 East West Highway, Suite 600 nw.focus();
difficult-to-inspect products (DIP) are provided later within this chapter. The application of Knapp tests for determining the detection rates is also mentioned there. 13507 - Berlin, Germany text-align: left;
step in the reliable supply of high-quality font: 12px tahoma, verdana, arial;
strOrderUrl = marked_all[0];
. West gives customers a solution by reducing time to market and single-source manufacturing. .tabBodyCol0 {
Finally, siliconization processes should be evaluated to minimize excess silicone levels. Since 2008, there has been heightened attention among manufacturers and regulators on particulate matter detection and control. Particulate matter limits as set in USP Chapter <789>, specifically for ophthalmic drug products, are described below: While particulate matter in drug products is regulated as described, there is no regulatory guidance on either particulate matter limits for primary packaging components or measurement. text-align: left;
}
We encourage all parties interested in the control of particulate matter in drug product manufacturing and distribution chains to provide their input on this standard, General Chapter <790> and other important USP standards by providing comments onPharmacopeial Forum. Bethesda, MD 20814 USA in the form of USP <1790> Visual Take an in-depth look at the science behind containment & delivery of
injectable medicines in the West Knowledge Center. color: black;
will be on Tel: +49 30 436 55 08-0 or -10 {
font-size: 13px;
}
hand to offer their views, and case studies height: 18px;
Inspection Life-Cycle 5. This standard provides manufacturers with procedures and specifications for detecting visible particulate matter and serves as a starting point for manufacturers working with regulators. PDA A Global Two Stage Approach within Visual Inspection. Finally, West offers 100% visually inspected components: Daikyo RSV, Daikyo RUV and Daikyo D Sigma components, as well as West Envision verification process and NovaPure components. packaged in amber containers. text-align: center;
4 1790 Visual Inspection of Injections / General Information First Supplement to USP 40-NF 35. As per USP <1790> 'VISUAL INSPECTION OF INJECTIONS' For amber container, 8000 to 10,000 lux level may require. 'captText' : 'tabCaptionLink',
width: 100px;
Additional guidance when inspecting these Daikyo RSV, Daikyo RUV and Daikyo D Sigma are trademarks of Daikyo Seiko, Ltd. USP 43 NF 38. font-size: 13px;
stay current on this important regulatory topic. Chapter <1790> with its number >1,000 is not mandatory; it's considered to be an explanatory text for the already published chapter <790> "Visible Particulates in Injections", which is mandatory in the US. if (strOrderUrl != ' ') {
through the prevention of glass delamination, by choosing appropriate formulations and according stability studies. Tel: +65 64965504 The use of packaging components designed to meet high-quality standards can aid in reducing the risk of rejected drug products. The terms "particle," .tabPagingArrowCell {
width: 1px;
General Inspection Level II, single sampling plans for normal inspection with an AQL of 0.65%. However, if the test sample has issues resultant from low clarity or high viscosity (e.g., emulsions, colloids, and liposomal preparations), or produces air or gas bubbles, Method 1 is unsuitable and Method 2 should be used. Copyright Parenteral Drug Association. }
The long-awaited new monograph <1790> of the US Pharmacopoeia about the visual inspection of injections finally came into force on August, 1st. Designated gowning areas and gowning requirements. direct guidance on how to inspect and what text-align: left;
Chapter <1790> with its number >1,000 is not . nw = open(strOrderUrl,"gmp_extwin");
Essentially Free: When injectable drug products are inspected and as described in USP <790>, no more than the specified number of units may be observed without magnification to contain visible particulates. long-term action },
Yet there continue to .tabBodyCol3 {
Particulates, if present, can interact with the injectable drug product and change the chemical consistency. important step also provides information on process performance and informs font: 11px tahoma, verdana, arial;
}
and the in-depth study of inspection },
Introduction3. Parent . ICH Q13: Final Version of Guideline for Continuous Manufacturing published, Cross Contamination in Steam Steriliser at US Sterile Manufacturer, Cross Contamination Risk: Production stopped, General Quality Assurance and GMP Compliance Topics, Solid Dosage Forms/Semi-Solid Dosage Forms, Herbal Drug Products/Cannabis/Radiopharmaceuticals. cursor: pointer;
USP Chapter <788> provides two methods for the determination of particulate matter: Method 1 (LO Particle Count Test) and Method 2 (Microscopic Particle Count Test). However, there are only very few tips for the fully-automated inspection, and there are no details referring to the qualification or re-qualification of fully-automated inspection processes. };
13507 - Berlin, Germany Shorty after that, a revised version was published in PF 41(6).